VCNX - Vaccinex's pepinemab combo study shows encouraging activity in lung cancer

Vaccinex (VCNX) announces results from the its CLASSICAL-Lung clinical trial in the journal Clinical Cancer Research.The Phase 1b/2 trial evaluated pepinemab, in combination with the immune checkpoint inhibitor Bavencio (avelumab) for the treatment of non-small cell lung cancer ((NSCLC)). The results demonstrate that combination appeared to halt or reverse tumor progression (partial response or stable disease). Among 21 evaluable immunotherapy naïve patients, five patients experienced partial responses, four patients evidenced clinical benefit at or greater than one year, and the disease control rate was 81%.Notably, the objective response rate with the combination therapy was higher than previously reported for single agent avelumab in the PD-L1-/low population.Among 29 evaluable patients who previously experienced disease progression during or following anti-PD-1/L1 immunotherapy, the subsequent combination treatment resulted in a DCR of 59%, including two partial responses and seven patients with durable clinical benefit of at least 23 weeks.Finally, exploratory biomarker analysis from biopsies demonstrated

For further details see:

Vaccinex's pepinemab combo study shows encouraging activity in lung cancer